Premium
CTL‐Based Cancer Preventive/Therapeutic Vaccines for Carcinomas: Role of Tumour‐Associated Carbohydrate Antigens
Author(s) -
Franco A.
Publication year - 2005
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2005.01596.x
Subject(s) - ctl* , cytotoxic t cell , antigen , cancer research , cd8 , linker , mhc class i , major histocompatibility complex , glycopeptide , cancer , biology , chemistry , immunology , biochemistry , genetics , antibiotics , computer science , in vitro , operating system
In this study, we discuss the use of glycopeptides containing tumour‐associated carbohydrate antigens (TACA) as preventive vaccines for carcinomas. The results of our recent studies suggest that CD8+ cytotoxic T cells are capable of recognizing small TACA in a conventional class I MHC‐restricted fashion. TACA‐specific T‐cell receptors are highly degenerate and their fine specificity includes the glycosylated amino acid linker together with the sugar moiety. TF, a disaccharide and Tn, its immediate precursor, are TACA largely expressed in carcinomas that can be successfully used as vaccines when conjugated to designer peptide backbones with optimal binding affinity for class I MHC molecules.